Varian to work with Google on new diagnostic AI platform
April 8, 2021 -- Radiation oncology firm Varian Medical Systems plans to work with Google Cloud to build artificial intelligence (AI) tools for radiation oncology organ segmentation using the Google Cloud AI Platform. Read More
Radium-223 treatment in men increases risk of bone fracture
April 6, 2021 -- Bone health agents should be mandatory to help prevent fractures in men who receive radionuclide therapy with radium-223 for prostate cancer, according to a study published online April 4 in Clinical Genitourinary Cancer. Read More
Vysioneer secures FDA clearance for brain tumor contouring software
April 5, 2021 -- The U.S. Food and Drug Administration (FDA) has cleared artificial intelligence (AI) firm Vysioneer's brain tumor autocontouring software, called VBrain. Read More
ASTRO survey finds rise in advanced-stage cancer
March 30, 2021 -- The disruption of cancer screening programs during the COVID-19 pandemic has had a very real impact. In a recent survey by the American Society for Radiation Oncology (ASTRO), 66% of radiation therapy practice leaders said that new patients are presenting with more advanced-stage cancers. Read More
Varian invests in Israeli microcatheter company
March 26, 2021 -- Radiation oncology firm Varian Medical Systems has invested in Israel-based company Bend It Technologies. Read More
Isotopia to supply MTTI with Lu-177
March 26, 2021 -- Isotopia Molecular Imaging announced it has inked a deal to supply biopharmaceutical company Molecular Targeting Technologies (MTTI) with its lutetium-177 (Lu-177) medical isotope for the development of new targeted radiotherapeutics. Read More
Study evaluates safety of new liver cancer treatment
March 25, 2021 -- Boston Scientific announced that its TheraSphere radioembolization treatment is safe and effective for patients with hepatocellular carcinoma, according to a 25 March presentation at the annual meeting of the Society of Interventional Radiology. Read More
IBA reports revenue rebound in 2020
March 25, 2021 -- Proton therapy developer Ion Beam Applications (IBA) bounced back with growth of 10.4% in revenues in 2020 after reporting reduced revenues for the first half of the year due to challenges presented by the COVID-19 pandemic. Read More
New radiotracer for neuroendocrine tumors appears safe
March 23, 2021 -- A new radiopharmaceutical based on lutetium-177 being tested for the treatment of neuroendocrine tumors is safe and effective and may allow physicians to cut the radiation dose patients receive by half, according to a study published online March 19 in the Journal of Nuclear Medicine. Read More
Novartis touts phase III prostate cancer study results
March 23, 2021 -- Novartis is highlighting results from a phase III study that has investigated the efficacy and safety of Lu-177 PSMA-617, a radioligand therapy for patients with prostate-specific membrane antigen-positive metastatic prostate cancer. Read More
Special Feature
IMV: Imaging boosts precision in radiation therapy
Radiation therapy is a relatively stable market, with procedure volume growing at an average annual rate of 2%. But major technological changes in radiation oncology are brewing under the surface, according to a new report by IMV Medical Information Division. Read more
VENDOR CONNECT